Doble B - Search Results

1

"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic.

Parisot JP, Thorne H, Fellowes A, Doig K, Lucas M, McNeil JJ, Doble B, Dobrovic A, John T, James PA, Lipton L, Ashley D, Hayes T, McMurrick P, Richardson G, Lorgelly P, Fox SB, Thomas DM. Parisot JP, et al. Among authors: doble b. J Pers Med. 2015 Oct 29;5(4):354-69. doi: 10.3390/jpm5040354. J Pers Med. 2015. PMID: 26529019 Free PMC article.

2

Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual.

Doble B, Harris A, Thomas DM, Fox S, Lorgelly P. Doble B, et al. Pharmacogenomics. 2013 Sep;14(12):1405-17. doi: 10.2217/pgs.13.142. Pharmacogenomics. 2013. PMID: 24024894

3

Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.

Doble B, Tan M, Harris A, Lorgelly P. Doble B, et al. Expert Rev Mol Diagn. 2015 Feb;15(2):235-54. doi: 10.1586/14737159.2014.929499. Epub 2014 Aug 21. Expert Rev Mol Diagn. 2015. PMID: 25142227 Review.

4

Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.

Doble B, Lorgelly P. Doble B, et al. Qual Life Res. 2016 Apr;25(4):891-911. doi: 10.1007/s11136-015-1116-2. Epub 2015 Sep 21. Qual Life Res. 2016. PMID: 26391884

5

Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015.

Lorgelly PK, Doble B, Knott RJ; Cancer 2015 Investigators. Lorgelly PK, et al. Among authors: doble b. Pharmacoeconomics. 2016 Feb;34(2):139-54. doi: 10.1007/s40273-015-0343-2. Pharmacoeconomics. 2016. PMID: 26547307

6

Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.

Doble B, John T, Thomas D, Fellowes A, Fox S, Lorgelly P. Doble B, et al. Lung Cancer. 2017 May;107:22-35. doi: 10.1016/j.lungcan.2016.05.024. Epub 2016 Jun 2. Lung Cancer. 2017. PMID: 27316470

7

Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.

Lorgelly PK, Doble B, Rowen D, Brazier J; Cancer 2015 investigators. Lorgelly PK, et al. Among authors: doble b. Qual Life Res. 2017 May;26(5):1163-1176. doi: 10.1007/s11136-016-1443-y. Epub 2016 Nov 9. Qual Life Res. 2017. PMID: 27830513 Free PMC article.

8

Clinical players and healthcare payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology.

Doble B, Lorgelly P. Doble B, et al. Per Med. 2015 Jan;12(1):9-12. doi: 10.2217/pme.14.81. Per Med. 2015. PMID: 29767540 No abstract available.

9

Prioritising the application of genomic medicine.

Doble B, Schofield DJ, Roscioli T, Mattick JS. Doble B, et al. NPJ Genom Med. 2017 Nov 21;2:35. doi: 10.1038/s41525-017-0037-0. eCollection 2017. NPJ Genom Med. 2017. PMID: 29263844 Free PMC article. Review.

10

The promise of personalised medicine.

Doble B, Schofield DJ, Roscioli T, Mattick JS. Doble B, et al. Lancet. 2016 Jan 30;387(10017):433-4. doi: 10.1016/S0140-6736(16)00176-8. Lancet. 2016. PMID: 26869572 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters